{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Weiner S"],"funding":["AD Strategic Fund and the Alzheimer&apos;s Association","ALF-agreement","NIA NIH HHS","University of Gothenburg","Alzheimer’s Association 2021 Zenith Award","European Union Joint Program for Neurodegenerative Disorders","Hjärnfonden, Sweden","National Institutes of Health","Swedish Research Council","Swedish Alzheimer Foundation","Olav Thon Foundation","Marie Skłodowska-Curie grant","Stiftelsen Gamla tjänarinnor","European Union Joint Programme – Neurodegenerative Disease Research","European Union’s Horizon Europe research and innovation programme","Alzheimer&apos;s Drug Discovery Foundation","UK Dementia Research Institute","Stiftelsen för Gamla Tjänarinnor","Erling-Persson Family Foundation","Bluefield Project","Hjärnfonden","NIH HHS","Alzheimerfonden","Swedish State Support for Clinical Research"],"pagination":["40"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10243080"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["<h4>Background</h4>Idiopathic Normal pressure hydrocephalus (iNPH) is a form of adult hydrocephalus that is clinically characterized by progressive gait impairment, cognitive dysfunction, and urinary incontinence. The current standard method of treatment involves surgical installation of a CSF diversion shunt. However, only a fraction of patients shows an alleviation of symptoms from shunt surgery. Thus, the purpose of this prospective explorative proteomic study was to identify prognostic CSF biomarkers to predict shunt responsiveness in iNPH patients. Further, we evaluated the ability of the core Alzheimer's disease (AD) CSF biomarkers phosphorylated (p)-tau, total (t)-tau, and amyloid-β 1-42 (Aβ<sub>1-42</sub>) to serve as predictors of shunt response.<h4>Methods</h4>We conducted a tand"],"journal":["Fluids and barriers of the CNS"],"pubmed_title":["Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalus."],"pmcid":["PMC10243080"],"funding_grant_id":["#2018-02532","2022-01324","#FO2017-0243 and #ALZ2022-0006","860197","ZEN-21-848495","#AF-930351, #AF-939721 and #AF-968270","UKDRI-1003","AF-980746","#1R01AG068398-01","#2017-00915","JPND2021-00694","#FO2022-0270","R01 AG068398","#ALFGBG-71320","101053962","#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C","#201809-2016862","JPND2019-466-236","#RDAPB-201809-2016615","#ALFGBG-715986 and #ALFGBG-965240"],"pubmed_authors":["Leinonen V","Luikku A","Weiner S","Junkkari A","Sauer M","Herukka SK","Rauramaa T","Kokkola T","Zetterberg H","Blennow K","Gobom J"],"additional_accession":[]},"is_claimable":false,"name":"Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalus.","description":"<h4>Background</h4>Idiopathic Normal pressure hydrocephalus (iNPH) is a form of adult hydrocephalus that is clinically characterized by progressive gait impairment, cognitive dysfunction, and urinary incontinence. The current standard method of treatment involves surgical installation of a CSF diversion shunt. However, only a fraction of patients shows an alleviation of symptoms from shunt surgery. Thus, the purpose of this prospective explorative proteomic study was to identify prognostic CSF biomarkers to predict shunt responsiveness in iNPH patients. Further, we evaluated the ability of the core Alzheimer's disease (AD) CSF biomarkers phosphorylated (p)-tau, total (t)-tau, and amyloid-β 1-42 (Aβ<sub>1-42</sub>) to serve as predictors of shunt response.<h4>Methods</h4>We conducted a tand","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2026-05-29T03:04:16.115Z","creation":"2025-02-19T02:37:46.646Z"},"accession":"S-EPMC10243080","cross_references":{"pubmed":["37277809"],"doi":["10.1186/s12987-023-00440-5"]}}